Skip to content
Gold Mining News – Lifestyle
Home
Sample Page
Author:
Century Therapeutics, Inc.
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
June 8, 2026
Century Therapeutics Reports First Quarter Financial Results and Business Updates
May 13, 2026
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
April 30, 2026
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
March 12, 2026